CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Immune Safety Avatar project aims to create a platform for assessing the safety and effectiveness of immunomodulatory therapies. It focuses on developing advanced nonclinical models and biomarkers to predict therapy responses and adverse effects, enhancing the transition from preclinical studies to human trials.
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy.
Existing nonclinical models do not adequately represent the complexity of the immune system and its interactions in both immunoncology and immunmediated diseases.
They also do not accurately reflect the diversity of response to new therapies that is seen in clinical medicine.We will, thus, constantly refine existing and develop new nonclini…
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Jena
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Enschede
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Belgium, Maasmechelen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
